Roche Has Over Five Weight-Loss Companion Medicines, CEO Says
- CEO bats away suggestion that Roche would buy an amylin asset
- Obesity drugs could be ‘backbone’ to treat range of diseases
Thomas Schinecker
Photographer: Betty Laura Zapata/BloombergThis article is for subscribers only.
Roche Holding AG has more than five medicines that it could combine with weight-loss drugs, Chief Executive Officer Thomas Schinecker said, as the Swiss drugmaker tries to crack the pharmaceutical industry’s fastest-growing market.
Combination therapy could help treat kidney, liver and heart disease, Schinecker said in an interview with Bloomberg Television on Tuesday. Roche is also working on experimental treatments that could help patients who’ve lost muscle mass due to rapid weight loss on the powerful new shots, Schinecker said.